tEditor's note: Seeking Alpha is proud to welcome Helixberg Insights as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access.
Viking Therapeutics: Why The Oral VK2735 Phase 2 Readout Could Send The Stock Soaring
Summary
- Oral VK2735 is strategically positioned to become a best-in-class oral GLP-1 therapy, with the Phase 2 trial data readout in H2 2025 serving as a critical catalyst.
- Phase 1 data for VK2735 represents the best efficacy and safety profile ever reported for an oral GLP-1 drug.
- The oral obesity market is projected to be the fastest-growing segment within the broader weight-loss market, driven by the superior convenience of oral formulations compared to injectable treatments.
- Similar read-outs, the option market and current valuation of VKTX of $3.64 Bn imply huge stock price upside to $52 upon positive trial data.
Helixberg is an independent biotech publication dedicated to providing concise and insightful briefings on major biotech catalysts and portfolio strategies. As a seasoned healthcare professional with extensive experience in the biotech sector and hedge fund industry, I founded this community to bridge the gap between complex biotech developments and actionable investment insights. With billions of dollars flowing into groundbreaking pharmaceutical research, the biotech industry moves at lightning speed. Throughout my career, I have been struck by how often traditional media fails to grasp the critical nuances of biotech investing and catalyst trading, frequently leaving investors misinformed and with suboptimal returns. Helixberg was born out of a passion to change this - to cut through the noise and deliver informed, data-driven perspectives that truly matter. Backed by deep expertise in analyzing clinical data, valuing biotech firms, and trading biotech stocks, this publication aims to be a trusted resource for investors, researchers, and professionals navigating the fast-evolving biotech landscape. Helixberg is entirely reader-supported, and I am grateful for every individual who engages with this platform. If you have any questions or ideas, I welcome your input - let’s explore the frontier of biotech investing together.
Analyst’s Disclosure:I/we have a beneficial long position in the shares of VKTX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
The opinions and views expressed in this article are solely those of Helixberg and its contributors and do not reflect the views of any affiliated or external organizations. The content may not be copied, distributed, published, or reproduced in whole or in part without the express written consent of Helixberg.
All third-party organizations mentioned in this article are referenced strictly for informational purposes. Their inclusion does not imply any affiliation, ownership, or licensing rights between those companies and Helixberg.
The content of this article is provided for informational purposes only and does not constitute financial, economic, legal, investment, accounting, or tax advice. Nothing in this publication should be construed as a recommendation or solicitation to buy, sell, or hold any financial product or to pursue any specific investment strategy.
Certain statements within this article may constitute "forward-looking statements," and there is no guarantee that these projections will be realized. Helixberg has no obligation to provide updates or changes to such information.
Past performance is not indicative of future results, and all investments carry inherent risks, including the potential for loss of principal. Helixberg and its contributors make no representations or warranties, express or implied, as to the accuracy, completeness, or reliability of the information presented. Any liability for direct, indirect, or consequential loss or damage arising from the use of this information is expressly disclaimed.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.